

## **Department of Clinical Biochemistry**

## Information for Clinicians

## **Assessment and Management of Lipids**

#### Lipid requests

In most people Cholesterol, HDL and Non-HDL measurement is used for screening and monitoring. Non-HDL cholesterol is used as an estimation of the total number of atherogenic lipoprotein particles; it is used to risk stratify patients and as a treatment target.

- Primary prevention target aims for a 40% reduction in Non-HDL.
- Secondary prevention targets aim for Non-HDL less than 2.5mmol/L

#### When are full lipid profiles required?

NICE CG181 states that a full lipid profile should be requested at least once before starting therapy. This should include Cholesterol, HDL, Non-HDL, LDL-c and Triglycerides. It does not need to be fasted.

#### Ensure a full lipid profile is requested:

- At least once before starting treatment
- In known hypertriglyceridaemia
- With mixed hyperlipidaemia of genetic aetiology
- When low HDL noted
- With risk factors for high triglycerides such as poorly controlled diabetes, alcohol excess or medications
- Monitoring cardiovascular disease

#### Lipid Management

<u>All clinicians</u> for primary and secondary prevention should now be using the NHSE National Lipid Pathway to guide treatment. This can be found at: <u>NHS Accelerated Access</u> <u>Collaborative » Summary of national guidance for lipid management</u> A screenshot of the main guidance is attached below

#### Summary of lipid management for Primary and Secondary Prevention

- All patients with raised cholesterol should be encouraged to eat a diet high in fruit, vegetables & wholegrains and low in saturated fat however it is the overall calorie intake which can lead to excess weight that is most important
- A Mediterranean diet is the most healthy option
- Those with diabetes should optimise their control and overall calorie consumption.

Ref.: PATH-18: Assessment and Management of Lipids Approved by: Beverley Harris, Consultant Clinical Scientist in Biochemistry Author: Dr Moya O'Doherty, Consultant Chemical Pathologist Date of Issue:  $5^{\text{TH}}$  November 2024 Version: 3.1 Approved on: 31/10/2024 Review date: 20/05/2027 Page 1 of 7

# Royal United Hospitals Bath

- Encourage physical activity: 150 mins moderate aerobic activity a week.
- See <u>https://www.nhs.uk/live-well/</u>

#### In primary prevention:

- Lifestyle optimisation should be supported for 3-6 months with further evaluation at this point.
- QRISK can be used to help decide if treatment is required (when >10% risk) however it would not be appropriate for non-HDL to be untreated long term if greater than 5.0mmol/L
- After deciding to start treatment, only high intensity statins should be used (Rosuvastatin/Atorvastatin)
- The statin dose should be optimised with lipid checks every 3 months until at target, then monitor yearly
- The target should be a non-HDL reduction of 40%
- Second line treatment is Ezetimibe and it should be noted that adding to statin therapy reduces LDL more than doubling the dose of statin

#### In secondary prevention:

- Prescribe Atorvastatin 80mg or Rosuvastatin 40mg
- Target non-HDL is <2.5mmol/L (or less than 1.8mmol/L) unless multiple risk factors or progressive disease where LDL less than 1.4mmol/L is more suitable
- Review every 3 months until target achieved then monitor yearly
- Second line agents are Inclisiran (if LDL >2.6mmol/L) or Ezetimibe (if LDL 1.8-2.6mmol/L)

#### **Statin Intolerance**

- Most patients tolerate these newer statins (90%)
- However if the above medications cannot be used Bempedoic acid, with or without Ezetimibe, is available for use in both primary and secondary prevention.
- The NHSE statin intolerant pathway is below:

https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2020/04/statin-intolerancepathway-v2.pdf

Further helpful charts can be found via these links:

https://thehealthinnovationnetwork.co.uk/wp-content/uploads/2024/06/Pathway-forsecondary-care-following-an-Acute-Cardiovascular-event.pdf

https://thehealthinnovationnetwork.co.uk/wp-content/uploads/2024/06/Lipid-optimisationpathway-for-secondary-prevention-in-primary-care-and-the-community.pdf

#### Liver Function

- Do not exclude statin treatment for people whose baseline ALT or AST levels are raised but are <3 x the upper limit of normal (ULN)
- Monitor liver function at 3 and 12 months after starting statin only
- Stop statin if ALT >3 x ULN

Ref.: PATH-18: Assessment and Management of Lipids Approved by: Beverley Harris, Consultant Clinical Scientist in Biochemistry Author: Dr Moya O'Doherty, Consultant Chemical Pathologist Date of Issue: 5<sup>TH</sup> November 2024 Version: 3.1 Approved on: 31/10/2024 Review date: 20/05/2027 Page 2 of 7



#### Creatine Kinase

- Only measure a baseline CK if the patient has myalgia. If CK levels are more than 5 x upper limit of normal do not start statin treatment, investigate and refer as necessary
- Do not routinely measure CK in treated asymptomatic patients. If it is necessary to measure CK and levels are raised but <5 x the upper limit of normal, either stop or reduce to a lower dose of statin once symptoms have resolved
- If CK levels are >5 x upper limit of normal, then stop statin immediately and refer to BNF

#### Familial Hypercholesterolaemia

- Familial Hypercholesterolaemia (FH) is common, with an estimated prevalence of 1 in 250
- This condition should be considered and patients referred if they have:
  - Total cholesterol (TC) >7.5mmol/L or LDL-cholesterol >4.9mmol/L AND
  - A family history of premature coronary heart disease in a 1<sup>st</sup> degree relative (defined as <60 years old) or a 2<sup>nd</sup> degree relative (defined as <50 years old)</p>
- We would also recommend referral in patients with a TC >9.0mmol/L or a non-HDL cholesterol >7.5mmol/L even in the <u>absence of a family history</u> of premature coronary heart disease.
- The lipid clinic will decide on the likelihood of FH and if suspected arrange appropriate genetic testing to confirm/exclude this diagnosis. If confirmed appropriate family cascade testing can be initiated by the clinic.
- In patients in whom Familial Hypercholesterolaemia (FH) is suspected do <u>NOT</u> use QRISK to decide on treatment, this will underestimate the true level of risk. It is in most instances reasonable to wait for patient to be seen in clinic before starting treatment.
- If a patient is started on treatment prior to being seen in clinic, please ensure that at least one full lipid profile has been requested beforehand.
- In general, the target for treatment is to lower the LDL by at least 50%

Ref.: PATH-18: Assessment and Management of Lipids Approved by: Beverley Harris, Consultant Clinical Scientist in Biochemistry Author: Dr Moya O'Doherty, Consultant Chemical Pathologist Date of Issue: 5<sup>TH</sup> November 2024



#### Mixed dyslipidaemias (raised cholesterol and raised triglycerides)

- Mixed dyslipidaemias are common. These patients have a total cholesterol >5.0mmol/L and raised triglycerides. This type of dyslipidaemia, is often observed in patients who are obese/overweight, are insulin resistant/have glucose intolerance or who consume alcohol in excess. In many instances this type of dyslipidaemia is very amenable to lifestyle intervention.
- However, advice should be sought if a patient with a mixed dyslipidaemia has a personal or family history of premature cardiovascular disease. These patients may have Familial Combined Hyperlipidaemia (FCH), which is an autosomal dominant inherited condition associated with an increased risk of cardiovascular disease.
- QRISK should also **NOT** be used to assess CV risk in a patient with suspected FCH

#### Hypertriglyceridaemia

- If triglycerides are >20 mmol/L consider urgent discussion with a lipid consultant. These patients may require immediate initiation of a Fibrate and urgent referral to secondary care. There is a significant risk of pancreatitis.
- If the triglyceride concentration is between 10-20mmol/L treat the cause and repeat a full lipid profile (after an interval of 5 days but within 2 weeks). Please refer to the lipid clinic if triglycerides are >10 mmol/L on more than one occasion.
- In all cases of hypertriglyceridaemia consider alcohol, obesity, diabetes, diet and medication as common possible causes.

#### **Referral to Lipid Clinic**

- Common secondary causes of dyslipidaemia should be excluded before referral. They include:
  - Raised BMI
  - Impaired glucose tolerance or diabetes
  - Excess alcohol
  - Hypothyroidism
  - Liver disease
  - Nephrotic syndrome
  - o Medications

## Royal United Hospitals Bath

- In general, the lipid clinic manages genetic causes of lipid abnormalities and primary or secondary prevention is managed in the community. A referral should only be made if considering a genetic condition or there is a specific issue that requires specialist input (see below). A referral is only indicated if a patient's dyslipidaemia persists after treatment of secondary causes and 3 months targeted management of adverse lifestyle/metabolic features.
- On the referral we would ask that the following tests have been ordered: HbA1c, TFT, U&E, LFT, and urine albumin creatinine ratio.
- The referral should include recent lipid profile, a full list of current medications, BMI, cardiovascular risk factors and family history.
- Any letter for advice or referral should be sent through the choose and book service eRS system

#### Please refer the following groups of patients:


- Suspected Familial Hypercholesterolemia (FH)
- Severe hypertriglyceridemia (1x triglycerides >20 mmol/L, 2x >10 mmol/L if no other cause evident)
- Some groups of patients with lower levels triglycerides than above benefit from being seen if they require behaviour modification.
- Intolerance to medications; please see statin intolerant pathway below
- Severe hypercholesterolemia (TC >9 or non-HDL-C >7.5 mmol/L)
- Patients who may be suitable for injectable Alirocumab or Evolocumab therapies in accordance with NICE Guidance (TAs 393 and 394)
  - FH without CVD but LDL-C persistently above 5 mmol/L
  - FH with CVD and LDL-C persistently above 3.5 mmol/L
  - Non-FH but \*high or \*\*very high risk of CVD with LDL-C persistently above 4 or 3.5 mmol/L respectively (\*High risk of CVD = disease in one vascular territory) (\*\*Very high risk of CVD = disease in two vascular territories or progressive disease despite lipid lowering treatment)

The lipid clinic does not administer Inclisiran as this is positioned in primary care in the National lipid pathway.

#### Pregnancy

Lipid-lowering medication is not recommended for 3 months prior to conception, during pregnancy, nor during breastfeeding.

# Royal United Hospitals Bath



Ref.: PATH-18: Assessment and Management of Lipids Approved by: Beverley Harris, Consultant Clinical Scientist in Biochemistry Author: Dr Moya O'Doherty, Consultant Chemical Pathologist Date of Issue: 5<sup>TH</sup> November 2024 Version: 3.1 Approved on: 31/10/2024 Review date: 20/05/2027 Page 6 of 7

© Royal United Hospitals Bath NHS Foundation Trust 05.11.2024

#### MANAGEMENT

This guidance applies to new patients and may also be taken into consideration for those already on stains at their annual review. If 40% reduction of non+HDL-C, or target levels are not achieved offer high intensity statists. Discuss with papelve who are stable on a low- or medium-intensity statis the likely benefits and potential risk of side effects if changed to a high-intensity statist when hey have a medication review and agree with the person whether a change is needed.

taré à insuctaion review als agree wui le person vincisté à clarge à readeux. Exettimble, allocuranté, evidocuranté, evidocuranté or indistant can be adéed when patients' LDL-C levels are not lowered enough with the maximally toterated dose of statism. If statins are contraindicated or not toterated and exestimble autien dose not control LDL-C well enough, bempedede add with exetemble is an option. Do not offer a fibratie, nicotinic add, bile add binder or omega-3 fatty adds alone or in combination with statin, for the prevention of CVD (cleck NICE RVS28 and acids alone o TA805 for exc tions).

#### PRIMARY PREVENTION RISK ASSESSMENT

Use QRISK3 version of the calculator (or QRISK2 if not available) Do not use this risk assessment tool for people with established CVD or those who are already al high risk of developing CVD because of FH or other inherited disorders of lipid metabolism.

high nak of developing CVU because of H H of other inherited disorders of lipid metabolism. De not use a risk assessment tool to assess CVD risk in people with type 1 diabetes, or eGFR < 60 mL/min1.73 m<sup>2</sup> and/or abuminuria (as already at high risk of developing CVD). Consider people aged 2.85 at increased risk of CVD because of age alroyed perturbative who smoke or have raised BP. I CRISK <10% over next 10 years, do not rule out treatment if there is an informed preference for taking a statin or a concern that risk may be underestimated.

Consider a lifetime risk tool (e.g. <u>QRISK3-lifetime</u>) to inform discussions on CVD risk and to motivate lifestyle changes, particularly for people with a 10-year score < 10%, and people < 40 who have CVD risk factors.

#### Additional Risk Factors

Auditional Nation & Work State CVD fisk scores including QRISK may underestimate risk in people who have additional risk because of underlying medical conditions or treatments. These include, but not limited to the following group of people; • obesity increases CVD risk (NICE CG189)

treated for HIV

- reaeto tor HV
   severe metali illness
   taking medicines that can cause dyslipidaemia such as antipsychotic medication, controceteroids or immunosuppressant drugs
   already taking medicines to treat CVD risk factors
   autommune disorders such as SLE, and other systemic inflammatory disorders

autommune disorders such as SLL; and order systemic insammatory disorders
 onordiablet (hypertyclaemia)
 significant hypertriglycoridaemia (fasting triglyceridaes 4.5-9.9mmol/L)
 recent risk factor changes e.g. quit smoking, BP or lipid treatment
 Consider socio-economic status as an additional factor contributing to CVD risk (if not already in the risk relation).

SPECIAL PATIENT POPULATIONS

#### Type 1 Diabetes

lie NICE recommends offering statins to patients with Type 1 diabetes as detailed in the orithm, it also states to consider statins in those aged 18 to 40 with type 1 diabetes, including algorithm, it also states to consider statins in those who have had diabetes for ≤ 10 years

Chronic Kidney Disease Offer alovastatin 20mg for the primary or secondary prevention of CVD to people with CKD (eGFR less than 60 mL/min/1.73m<sup>2</sup> and/or albuminuria) Increase the dose if target is not achieved and eGFR is 30 mL/min/1.73m<sup>2</sup> or more. Agree the use of higher doses with a renal specialist if eGFR is less than 30 mL/min/1.73m<sup>2</sup>

Statins in Pregnancy and Lactation Statins in Pregnancy and Lactation Statins should be stopped 3 months before attempting to conceive and not be restarted until breastfeeding is finished. Stop statins if pregnancy is a possibility. ABBREVIATIONS

ALT: alanine aminotransferase AST: aspartate aminotransferase CHD: coronary heart disease CKD: chronic kidney disease CKD: chronic kidney disease FH: familial hypercholesterolaemia JBS: Joint Effinis Societies LDL-C: low density lipoprotein cholesterol

Neterences JBS3. 2014. <u>www.ibs3irink.com/pages/li.htm</u> Kirsten et al. 2005. Hospital Pharmacy 40(8):687-692 Navarese et al. 2015. Annais of internal medicine 163(1):40-51 Son Jun Hong et al. 2018. Clinical therapeutics 40(2):226-241.e4

nces

REVIATIONS non-HDL-C: non-high density lipoprotein choleste PCSK9: proprotein convertase subtiliain kexin 9 monoclonal antibody inhibitor QOF: Quality and Outcomes Framework SLE: systemic lupus erythematosus SPC: summary of product characteristics TC: total cholesterol

NICE 2016. TA385 www.nice.org.uk/guidance/ta385 NICE 2016. TA393 www.nice.org.uk/guidance/TA393 NICE 2016. TA394 www.nice.org.uk/guidance/TA394

Ар Statin dose mg 40

Fluvastatin Pravastatin Simuastatin astatin + Ezetimibe 10mg

ING WITH AVAILABLE THERAPIES

80

Low intensity statins will produce an LDL-C reduction of 20-30% Medium intensity statins will produce an LDL-C reduction of 31-40% N High intensity statins will produce an LDL-C reduction above 40% Simvastatin 80mg is not recommended due to risk of muscle toxicity

Sinvestatin 80mg is not recommended due to risk of muscle toxicity
Rosuvastatin may be used as an alternative to advorvastatin if compabile with other
drug therapy. Some people may need a lower starting dose (see BNF).
Lowinedum intensity statins should only be used if indierance or drug interactions.
Externible when combined with any statin is likely to give greater reduction in nonHDL-C or LD-C than doubling the dose of the statin.
PCSSK9 (INCE TA333, TA349) alone or in combination with statins or ezetimibe
produce an additional LD-C reduction of approximately 50% (range 25-70%).
Bempedota cald when combined with exterline (FA640) produces an additional
LD-C reduction of approximately 25% (range 22-33%).
Inclisitran (TA733) alone or in combination with statins or ezetimibe
produces an
additional LD-C reduction of approximately 50% (range 45-5%) but no clinical
outcome evidence is currently available.
MONITORING MONITORING

#### Baseline Measurements

EXTENT OF LIPID LOWER

Baseline Measurements In addition to full lipid profile, measure renal, thyroid and liver profiles (including albumin) and HAA to te exclude secondary causes and co-morbidities. Measure baseline liver transaminase (ALT or AST) before starting a statin. Measure CK4 funcexplained muscle pain before starting a statin. CK should not be measured routinely especially if a patient is asymptomatic. 

	Lipid Profile	ALT or AST	Lipid Profile	ALT or AST		
Baseline	1	1	1	1		
2-3 months	1	1	1	1		
	If targets are not met, and up-titration is agreed, repeat full lipid profile and ALT or AST within 2-3 months of each up-titration of statin dose or addition of ezetimibe as required					
12 months	1	1	1	1		

Provide annual medication reviews for people taking statins to discuss effectiveness of therapy, medicines acherence, lifestyle modification and address CVD risk factors. "Offer in secondary prevention, and consider in primary prevention an annual non-fasting full lipid profile to inform the discussion around effectiveness of lipid lowering therapy and any medicines non-whenever. Monitoring Repeat full lipid profile is non-fasting. Do not stop statins because of an increase in blood glucose level or HbA1c

Advise that the risk of muscle pain, tenderness or weakness associated with statins is small and the rate of severe muscle adverse effects (rhabdomyolysis) is extremely low

#### Liver Transaminases

Liver Iransaminases Measure liver transaminase within 3 months of starting treatment and then within months of every additional up titration and then again at 12 months, but not again unless clinically indicated.

unless clinically indicated. If ALT or AST are greater than 3 times the upper limit of normal then do not initiate a statin or discontinue statin therapy already prescribed and repeat the LFTs in a month. If ALT or AST are <u>elevated</u> but are less than 3 times the upper limit of normal then: • O on it routinely exclude from statin treatment • Continue the statin and repeat in a month.

NICE 2008. CG71 www.nice.org.uk/guidance/cg71 NICE 2021. TA694 www.nice.org.uk/guidance/TA694 NICE 2021. TA733.www.nice.org.uk/guidance/TA733 NICE 2022. TA805 www.nice.org.uk/g NICE 2023. NG238 www.nice.org.uk/g NICE 2023. CG189 www.nice.org.uk/g

Escalate lipid lowering therapy if on-HDL-C reduction from baseline ≤ 40% Aim for an LDL-C of ≤ 2.0 mmol/L, or non-HDL-C of ≤ 2.6 mmol/L at least\* non-HDL-C <2.5mmol/L (LDL-C <1.8mmol/L) Fit Optimise tipd lowering therapy to achieve at least 50% reduction to LDL-C (or non-HDL-C). Consider exzemble to reduce CVD ins further, even if the NICE lipid target for secondary prevention of CVD is met. "LDL-can dno-HDL-C levels should be reduced as much as possible in people with CVD. Consider a personalised target, as clinically indicated, e.g. JBS3

with CVU. Conserve a performance of the conserve recommendation consensus recommendation Non-HDL-C = TC minus HDL-C = non-HDL-C minus (Fasting trighycerides\*2.2) "valid only when fasting trighycerides are less than 4.5 mmol/L SPECIALIST SERVICES DCCC reliance SPECIALIST SERVICES

# LUL-C cannot be calculated using Friedewald's formula if TG >4.5. Discuss with your lab. Consider using an alternative equation (eg Sampson, doi: 10.1001/jamacardio.2020.0013) or beta-quantificat \$ labs don't report calculated LDL-C beyond one decimal point STATIN INTOLERANCE

Statin intolerance is defined as the presence of clinically significant a from statin therapy that are considered to represent an unacceptable patient or that may result in adherence to therapy being compromise ence of clinically significant adverse effects o represent an unacceptable risk to the For people who are intolerant of the recommended statin treatment see the NHSE AAC statin intolerance algorithm, available on the NHSE AAC page (Click here)

ACCELERATED ACCESS COLLABORATIVE

NHS

"This summary accurately reflects NICE guidance and JBS3 recommendations", NICE March 2024



Issue	Status	Date	Reason for Change	Authorised
1.0	Published	April 2023	First Issue	AMS Lead
2.0	Published	February 2022	Updated Version	Clinical Director of Pathology
3.0	Published	May 2024	Update version	Clinical Director of Pathology
3.1	Published	Oct 24	Changes to add more reflections on new lipid pathways	Moya O'Doherty

Ref.: PATH-18: Assessment and Management of Lipids Approved by: Beverley Harris, Consultant Clinical Scientist in Biochemistry Author: Dr Moya O'Doherty, Consultant Chemical Pathologist Date of Issue: 5<sup>TH</sup> November 2024

**Royal United Hospitals Bath** 

/ TARGETS

Scope of specialist service available locally may include; lipid clinic, PCSK8 clinic (offering initiation and subsequent follow up). FH genetic diagnosis and cascade testing, lipoprotein apheresis service. NICE eligibility criteria for PCSK9 and fastii LDL-C thresholds are summarised below.					
NICE TA393 Alirocumab Without CVD With CVD					
NICE TA394 Evolocumab High risk 1 Very high risk	sk ²				
Primary non-FH or mixed Not recommended LDL C > 4.0 mmoL/L LDL C > 3. mmoL/L	5				
Primary heterozygous-FH LDL C > 5.0 mmoL/L LDL C > 3.5 mmoL/L					
schaerinis troke; PAD. <sup>1</sup> Recurrent CV events or CV events in more than 1 vasoular bed (that is, obyvascular dasses). Bempedolo: actid/ezzetimbe and inclisiran are available in primary care and do not require initiation to specialist services. <sup>1</sup> PCSK0 imay be available for prescribing i primary care: see local initiation pathways.					
TRIGLYCERIDES					
Triglyceride Action concentration					
	Refer to lipid clinic for urgent specialist review if not a result of excess alcohol or poor glycaemic control. At risk of acute pancreatitis.				
4.5 - 9.9mmoltL If non-fasting triglycerides are greater than 4.5mmolL, repeat with a fasting TG measurement. Be aware that the CVD risk may be underestimated by risk assessment tools, optimise the management of other CVD risk factors present and seek specialist advice if non HDL-C concertation is > 7.5 mmoltitle.	nt				
Icosapent ethyl (TA805)					
Check fasting triglycerides levels.					
<ul> <li>Manage secondary causes of hypertriglyceridaemia.</li> </ul>					
<ul> <li>Consider icosapent ethyl (TA805) if patient has established cardiovascular disease (secondary prevention) and - on statins and fasting TG ≥ 1.7mmol/L and LDL-C* between 1.04<sup>t</sup> and ≤2.6mmol/L</li> <li>See table above and refer as appropriate.</li> </ul>					
* See table above and refer as appropriate. * LDL-C cannot be calculated using Friedewald's formula if TG >4.5. Discuss with your lab. Consider					



continue statin and repeat again in 6 months